Aligos Q2 2021 net loss $29.8M; $83.6M stock offering; pipeline advances

Aligos Therapeutics, Inc.

Net loss $29.8M ($0.79 diluted EPS) vs $20.8M ($7.40) year ago; R&D spend $24.6M.
Cash & investments $190.7M at June 30, 2021, down from $243.5M at Dec 2020.
Gross proceeds of $83.6M from July 2021 follow-on stock offering (4.4M shares at $19.00).
STOPS and CAM programs dosing in CHB cohorts; data expected H1 2022.
CTA filed for ASO ALG-020572; NASH drug ALG-055009 CTA on track for Q3 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.